Clinical Trials · NCT05339529

Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Name: Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/AThymosin Alpha-1

Phase: N/A
Recruitment status: Completed
Sponsor: Nanjing Medical University
Enrollment: 600
Start date: Jul 2022
Locations: 15 sites, China
Primary endpoint: 7-day postoperative organ dysfunction burden assessed by mean daily SOFA score

View Thymosin-Alpha-1 compound reference